US FDA advises ‘stepwise’ approach in long-awaited biosimilar guidelines
This article was originally published in Scrip
Executive Summary
After months of anticipation, the US FDA on 9 February revealed three draft guidance documents intended to help makers of biosimilars understand the agency's expectations about developing the products and how to interact with regulators through the approval process.